Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health
Owen joins to lead new phase of growth for the medical device company in clinical trial, diagnostic, and reference laboratory applications
CAMBRIDGE, Mass., Feb. 19, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and YourBio Health, a pioneer in remote blood collection technology, today announced the appointment of Paul Owen as Chief Executive Officer of YourBio Health and CEO-Partner of Flagship Pioneering.
Owen joins YourBio Health and Flagship after a corporate leadership and strategic planning career spanning more than 35 years. He was most recently Board Director and President of Oncodea, an early cancer detection company, and a Managing Partner for Trusted Health Advisors, overseeing diagnostics, companion diagnostics, population health, and digital health. He has previously held leadership roles across digital health and health care solutions including with imaware™, OneOme, and Mayo Medical Laboratories.
"Paul's strategic vision and leadership will be instrumental as YourBio Health continues its mission to humanize, decentralize, and transform the blood collection process, which we envision serving the entire healthcare industry," said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering. "We are pleased to welcome him to the Flagship leadership network and look forward to his impact on YourBio Health."
The company's Touch-Activated Phlebotomy (TAP®) device is the first push-button blood collection technology. Using microneedles to achieve virtually painless blood draws, TAP products are used today in clinical trial, diagnostic, and wellness settings and enable easy-to-use and reliable at-home blood collection. The Flagship-founded company has existing partnerships with biopharmaceutical companies, leading genetic companies, and academic research hospitals. Since commercial launch, TAP devices have been used in multiple clinical trials and in millions of blood collections.
"There is enormous potential in making blood collection easier and more accessible to better treat and preempt diseases," said Ignacio Martinez, General Partner, Flagship Pioneering and Executive Chairman, YourBio. "Now is the moment for YourBio to build on the demonstrated utility of its technology, and Paul is the right leader to meet that moment."
"I am pleased to have the chance to lead YourBio Health and collaborate with the exceptional and forward-thinking leadership teams at both companies," said Paul Owen. "Throughout my career, I've seen the challenges created by phlebotomy – the pain, discomfort and logistical challenges for trial sponsors, patients, clinicians and healthcare organizations. I look forward to scaling and growing YourBio so this technology can help eliminate those challenges and deliver a better-quality patient experience."
The company also announced today concurrent appointments to its leadership team, adding medical device product innovation, clinical strategy, and commercialization expertise.
About Paul Owen
Paul Owen brings over 35 years of experience in corporate leadership and strategic planning, with a proven ability to achieve business targets.
Prior to joining YourBio, he served as Board Director and President of Oncodea, an early cancer detection company, and a Managing Partner for Trusted Health Advisors, overseeing diagnostics, companion diagnostics, population health, and digital health. He previously served as President and Interim CEO of imaware™, which provides a digital health platform experience that offers advanced home-based testing and monitoring. Prior, Owen was the Vice Chair – Product, for Global Business Solutions of Mayo Clinic and Global Commercial Leader of Mayo Medical Laboratories.
Owen previously served as Chief Business Officer and COO for Kailos Genetics and CEO of OneOme, an innovator in precision medicine and pharmacogenetics co-founded by Mayo Clinic. While he led OneOme, Fast Company recognized it as one of the top 50 most innovative companies in the world and #2 in biotech. Inc. Magazine awarded it the 2019 MedTech Breakthrough Award for Best Overall Genomics Company. Owen also actively serves as a Board Director and Executive Advisor for a number of life sciences companies.
He received his B.S. from the University of Wisconsin-Stout, the polytechnic university of the University of Wisconsin System.
About Flagship Pioneering
Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $60 billion in aggregate value. Flagship is operating with $14 billion of assets under management as of its latest capital raise, announced in July 2024. The current Flagship ecosystem comprises over 40 companies, including Foghorn Therapeutics (NASDAQ:FHTX), Moderna (NASDAQ:MRNA), Sana Biotechnology (NASDAQ:SANA), Generate Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.
About YourBio Health
YourBio Health is a medical device company that strives to take the pain out of the blood draw experience with its 'Touch-Activated Phlebotomy' (TAP®), the world's first push-button blood collection technology. TAP products eliminate barriers to blood collection by allowing a capillary blood sample to be collected from any physical location without the pain of a fingerstick or the need for traditional phlebotomy. Backed by the latest science, data management technology, and certified central labs, YourBio Health seeks to revolutionize and humanize the blood collection process serving clinical trials, diagnostic, wellness, and reference laboratory applications. YourBio was founded by Flagship Pioneering in 2011.
Media Contact
View original content to download multimedia:https://www.prnewswire.com/news-releases/flagship-pioneering-appoints-paul-owen-as-ceo-partner-and-ceo-of-yourbio-health-302379939.html
SOURCE Flagship Pioneering